Nick Leschly at JPM20 (Jeff Rumans)
September 12, 2023 07:36 AM EDTUpdated 11:43 AM
People
Cell/Gene Tx

Up­dat­ed: 2sev­en­ty lays off 40% of staff, prunes CAR-T pipeline as Nick Leschly steps down as CEO

Amber Tong

Katherine Lewin

News Reporter

With an ear­ly-stage CAR-T un­der clin­i­cal hold, 2sev­en­ty bio is slash­ing its head­count by 40% and cap­ping spend­ing on some pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

A service from the Financial Times